INNOV AD nv – Trademark Portfolio

Entity Type: 98

INNOV AD nv holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include FORTIPRIM.

Postbaan 69

B-2910 Essen

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FORTIPRIM
FORTIPRIM
Registered 2025

Trademark Classifications

INNOV AD nv's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

31
Natural Agricultural Products (1 filing)

Raw and unprocessed agricultural, aquacultural, horticultural and forestry products

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does INNOV AD nv have?

INNOV AD nv has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does INNOV AD nv file in?

INNOV AD nv files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 31 (Natural Agricultural Products), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are INNOV AD nv's most well-known trademarks?

INNOV AD nv's registered trademark portfolio includes well-known marks such as FORTIPRIM. These are among 1 currently registered trademark in the portfolio.

What is INNOV AD nv's trademark registration success rate?

INNOV AD nv has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.